Abstract
Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given on the use of irreversible MAO-Is as well as on reversible ones. Benefit and side effects are reported for Parkinsons disease, Alzheimers dementia, depression syndrome and panic disorders. The preclinical and clinical effects of selegiline with regard to neuroprotection are highlightened and the conclusion is drawn that there is good evidence for a clinical neuroprotective capacity based on the assumption that the 50 percent recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline. There is also a focus on selegilines metabolism to amphetamine and metamphetamine. In order to avoid any such effects of metabolic compounds on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metabolism to amphetamine and metamphetamine is described in detail. Developments in MAO-I research are discussed in detail as there are moclobemide, lacabemide, rasagiline. Interactions of MAO-I with tricyclics and serotonin selective reuptake inhibitors (SSRIs) are described as there is mentioning of interactions of MAO-Is with other compounds in general. Tables and figures report on clinical studies and on pharmacological properties of MAO-Is.
Keywords: monoamine oxidase inhibitors, selegiline, rasagiline, moclobemide, lacabemide, neuroprotection
Current Medicinal Chemistry
Title: Clinical Applications of MAO-Inhibitors
Volume: 11 Issue: 15
Author(s): P. Riederer, L. Lachenmayer and G. Laux
Affiliation:
Keywords: monoamine oxidase inhibitors, selegiline, rasagiline, moclobemide, lacabemide, neuroprotection
Abstract: Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given on the use of irreversible MAO-Is as well as on reversible ones. Benefit and side effects are reported for Parkinsons disease, Alzheimers dementia, depression syndrome and panic disorders. The preclinical and clinical effects of selegiline with regard to neuroprotection are highlightened and the conclusion is drawn that there is good evidence for a clinical neuroprotective capacity based on the assumption that the 50 percent recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline. There is also a focus on selegilines metabolism to amphetamine and metamphetamine. In order to avoid any such effects of metabolic compounds on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metabolism to amphetamine and metamphetamine is described in detail. Developments in MAO-I research are discussed in detail as there are moclobemide, lacabemide, rasagiline. Interactions of MAO-I with tricyclics and serotonin selective reuptake inhibitors (SSRIs) are described as there is mentioning of interactions of MAO-Is with other compounds in general. Tables and figures report on clinical studies and on pharmacological properties of MAO-Is.
Export Options
About this article
Cite this article as:
Riederer P., Lachenmayer L. and Laux G., Clinical Applications of MAO-Inhibitors, Current Medicinal Chemistry 2004; 11 (15) . https://dx.doi.org/10.2174/0929867043364775
DOI https://dx.doi.org/10.2174/0929867043364775 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening
Current Drug Safety Brain Ageing, Cognition and Diet: A Review of the Emerging Roles of Food-Based Nootropics in Mitigating Age-related Memory Decline
Current Aging Science Bone Marrow-Derived Mesenchymal Stem Cells Contribute to the Reduction of Amyloid-β Deposits and the Improvement of Synaptic Transmission in a Mouse Model of Pre-Dementia Alzheimer’s Disease
Current Alzheimer Research Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Chronic Kidney Disease and Sleeping Disordered Breathing (SDB)
Current Hypertension Reviews HIV Genes Diversify in B Cells
Current HIV Research Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
Current Alzheimer Research Data Tagging in Medical Images: A Survey of the State-of-Art
Current Medical Imaging Pentameric models as alternative molecular targets for the design of new antiaggregant agents
Current Protein & Peptide Science Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study
Anti-Cancer Agents in Medicinal Chemistry Editorial: [Hot Topic HIV and Substance Abuse]
Current HIV Research Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research